**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 55373

**Manuscript Type:** REVIEW

**Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of *in vivo* studies**

Al-Dhamin Z *et al*. BM-MSCs in liver fibrosis

Zaid Al-Dhamin, Ling-Di Liu, Dong-Dong Li, Si-Yu Zhang, Shi-Ming Dong, Yue-Min Nan

**Zaid Al-Dhamin, Ling-Di Liu, Dong-Dong Li, Si-Yu Zhang, Shi-Ming Dong, Yue-Min Nan,** Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University & Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, Shijiazhuang 050051, Hebei Province, China

**Author contributions:** Al-Dhamin Z and Nan YM designed the work, performed the extensive literature search, and drafted the manuscript; Al-Dhamin Z and Liu LD analyzed and interpreted the data; Al-Dhamin Z, Zhang SY, and Dong SM provided important intellectual content by generating the figures and tables; Al-Dhamin Z and Li DD reviewed and edited the manuscript; Nan YM revised the work critically and approved the final version to be published.

**Supported by** Key Research and Development Program of Hebei Province, No. 19277779D; and The Program of Introduce International Intelligence of Hebei Province.

**Corresponding author: Yue-Min Nan, MD, PhD, Director, Doctor, Professor,** Department of Traditional and Western Medical Hepatology, Third Hospital of Hebei Medical University & Hebei Key Laboratory of Mechanism of Liver Fibrosis in Chronic Liver Disease, No. 139 Ziqiang Road, Shijiazhuang 050051, Hebei Province, China. nanyuemin@163.com

**Received:** August 21, 2020

**Revised:** October 31, 2020

**Accepted:** November 13, 2020

**Published online:**

**Abstract**

Although multiple drugs are accessible for recovering liver function in patients, none are considered efficient. Liver transplantation is the mainstay therapy for end-stage liver fibrosis. However, the worldwide shortage of healthy liver donors, organ rejection, complex surgery, and high costs are prompting researchers to develop novel approaches to deal with the overwhelming liver fibrosis cases. Mesenchymal stem cell (MSC) therapy is an emerging alternative method for treating patients with liver fibrosis. However, many aspects of this therapy remain unclear, such as the efficiency compared to conventional treatment, the ideal MSC sources, and the most effective way to use it. Because bone marrow (BM) is the largest source for MSCs, this paper used a systematic review approach to study the therapeutic efficiency of MSCs against liver fibrosis and related factors. We systematically searched multiple published articles to identify studies involving liver fibrosis and BM-MSC-based therapy. Analyzing the selected studies showed that compared with conventional treatment BM-MSC therapy may be more efficient for liver fibrosis in some cases. In contrast, the cotreatment presented a more efficient way. Nevertheless, BM-MSCs are lacking as a therapy for liver fibrosis; thus, this paper also reviews factors that affect BM-MSC efficiency, such as the implementation routes and strategies employed to enhance the potential in alleviating liver fibrosis. Ultimately, our review summarizes the recent advances in the BM-MSC therapy for liver fibrosis. It is grounded in recent developments underlying the efficiency of BM-MSCs as therapy, focusing on the preclinical *in vivo* experiments, and comparing to other treatments or sources and the strategies used to enhance its potential while mentioning the research gaps.

**Key Words:** Bone marrow; Mesenchymal stem cells; Liver fibrosis; *In vivo*; Efficiency

Al-Dhamin Z, Liu LD, Li DD, Zhang SY, Dong SM, Nan YM. Therapeutic efficiency of bone marrow-derived mesenchymal stem cells for liver fibrosis: A systematic review of *in vivo* studies. *World J Gastroenterol* 2020; In press

**Core Tip:** Bone marrow (BM)- mesenchymal stem cells (MSCs) are a promising therapy for liver fibrosis. However, several aspects, such as efficiency, of this treatment are vague. This review summarizes the recent advances and effectiveness of BM-MSC therapy, its mechanisms, and related factors by focusing on preclinical *in vivo* experiments. While BM-MSCs appear to be effective in some cases, cotreatment appears to be a better option. Studies on strategies, implementation routes, and cotreatments are helping to strengthen the efficiency. While the potential of this therapy continues to advance, research is still needed to achieve full potential.

**INTRODUCTION**

The worldwide incidence of liver fibrosis has been increasing steadily in recent years; even though antiviral agents are widely used, the ultimate treatment for liver fibrosis is liver transplantation. Because transplants are not available in many countries and when they are, high costs and organ shortages cause this to be an unfeasible option for many patients. Development of curative therapies for end-stage liver disease is a necessity. Stem cell transplantation represents a promising solution because it involves recovery of the liver and production of hepatic stem cells (HSCs) in sufficient quantities to overcome the shortage of liver donors. Hepatocyte expansion from HSCs facilitates both physiological turnover and homeostatic regeneration[1].

Mesenchymal stem cells (MSCs) boast the benefits of being acquired relatively easily and stimulating low immunogenicity[2]. These cells are also characterized by a self-renewal ability and a capacity to differentiate into cells of various lineages, including osteoblasts, adipocytes, and chondrocytes[3]. MSCs also elicit less of an ethical concern because they do not originate from somatic cells. Their transplantation is considered safe and has been widely assessed in clinical settings and various diseases, yielding promising results[4].

Because bone marrow (BM) is the largest supplier of MSC sources, we focused this work on BM-MSC transplantation for liver fibrosis and its therapeutic efficiency. Many elements affect the therapeutic efficacy of BM-MSCs, such as culture method, strategies, and transplantation routes. Thus, understanding liver regeneration through BM-MSCs is crucial to offer new perspectives for treatment of liver diseases. This includes the underlying therapeutic mechanism that facilitates alleviation of liver fibrosis, its efficiency compared to other treatments, or dependence on the transplantation route and the strategies used for the procedure. This review outlines the recent advances of BM-MSCs for liver fibrosis, the main aspects of its utility steps, and their therapeutic effects on liver fibrosis to address questions regarding efficacy and gaps in the knowledge, opening a new path toward further studies (Figure 1).

**LIVER FIBROSIS**

Liver fibrosis is the extreme accumulation of extracellular matrix (ECM) proteins, including collagen, and appears in most chronic liver diseases. Distinct types of hepatotoxic agents produce mediators that induce inflammatory actions in hepatic cell types. Following chronic liver injury, symptoms associated with advanced hepatic fibrosis will appear. When advanced, liver fibrosis results in cirrhosis, liver failure, and portal hypertension, often requiring liver transplantation[5]. Alternatively, it can be resolved if the underlying cause is removed or through the use of an antifibrotic drug or cell therapy (Figure 2). It is possibly a reversible response that resulted from either hepatic insults generated by different chronic diseases, such as nonalcoholic fatty liver disease[6] or repetitive chronic liver injury induced by hepatitis, fat deposition, and continued alcohol consumption[7,8]; for both, the liver may accumulate aberrant myofibroblasts and ECM thus generating liver fibrosis. Depending on the inducing liver disease, liver fibrosis pathogenesis differs; for example, schistosomiasis induces liver fibrosis by accumulating parasitic ova and periocular granulomas in portal veins[9]. Wilson’s disease (or hepatolenticular degeneration), caused by a mutation in the Wilson disease protein (*ATP7B*) gene, frequently induces liver fibrosis[10]. Furthermore, it has recently been found that metabolic syndromes, including obesity, insulin resistance, and diabetes, are closely related to end-stage liver fibrosis[11].

Physiologically speaking, liver fibrosis is a healing response to liver injury. It is characterized by excessive deposition of ECM proteins as an outcome of different chronic liver diseases, including viral hepatitis and alcoholic or nonalcoholic steatohepatitis[5,12]. Liver fibrosis is beneficial at first because it can encapsulate the injury and is considered a reversible process at this stage[13,14]; however, it ultimately develops into advanced fibrosis or cirrhosis, which might be irreversible and impairs liver function that leads to subsequent morbidity and mortality[15].

After a severe liver injury, parenchymal cells regenerate and substitute the necrotic or apoptotic cells associated with an inflammatory response and an incomplete ECM deposition. The liver regeneration fails if the hepatic injury persists, and hepatocytes are replaced with abundant ECM containing fibrillar collagen. Depending on the origin of the liver injury, the distribution of this fibrous material differs. In chronic cholestatic disorders and chronic viral hepatitis, the fibrotic tissue is first located around portal tracts. In alcohol-induced liver disease, it is instead situated in pericentral and perisinusoidal areas[16]. Liver fibrosis is related to significant alterations in the quantity and composition of ECM[17]. In advanced stages, the liver holds about six times more ECM than ordinary, including collagens (I, III, and IV), fibronectin, undulin, elastin, laminin, hyaluronan, and proteoglycans[18]. Decreased activity of ECM-removing matrix metalloproteinases (MMPs) is mainly related to the overexpression of their inhibitors (*i.e*. TIMPs)[12].

Succeeding a chronic injury, HSCs, the primary ECM-producing cells[19], activate and transdifferentiate into myofibroblast-like cells, acquiring contractile, proinflammatory, and fibrogenic properties[20,21]. The activated HSCs accumulate at the spots of tissue repair, discharging significant ECM amounts and regulating ECM degradation. Kupffer cells (KCs) are the primary producer of PDGF, which is the main mitogen for activated HSCs. At the transcriptional and posttranscriptional levels, collagen synthesis in HSCs is regulated[22].

There is a complex interplay among different hepatic cell types the occurs during hepatic fibrogenesis. Many hepatotoxic agents can damage hepatocytes[23]; these damaged hepatocytes release reactive oxygen species (ROS) and fibrogenic mediators and induce white blood cell recruitment *via* inflammatory cells. Apoptosis of damaged hepatocytes stimulates the fibrogenic actions of liver myofibroblasts[23]. Inflammatory cells activate HSCs to secret collagen, emit inflammatory chemokines, and modulate lymphocyte activation[24,25]. Consequently, a vicious circle of inflammatory and fibrogenic cells stimulating each other occurs[26]. Fibrosis is affected by different T helper subsets, with the Th2 response being associated with more active fibrogenesis[27]. KCs play a main role in liver inflammation by releasing ROS and cytokines[28,29]. Also, changes in the composition of the ECM can directly promote fibrogenesis. Fibrinogen, type IV collagen, and urokinase-type plasminogen activator stimulate resident HSCs by activating latent cytokines, such as transforming growth factor (TGF)-β1[30]. Fibrillar collagens can attach and stimulate HSCs *via* the discoidin domain receptor and integrins. Furthermore, altered ECM can act as a reservoir for growth factors and MMPs[31].

**BM-MSCs**

***Identification of MSCs***

Modern science has witnessed an essential thrust in stem cell research[32], identifying their presence in limited amounts in adult tissues, such as adipose tissue (AD-MSCs)[33,34], umbilical cord (UC) tissue[35], amniotic fluid[36,37], breast milk[38,39], synovium[40], BM-MSCs[41], placental cells[42], dental pulp[43], lung, and liver (both adult and fetal)[44]. They are multipotent cells capable of differentiating into distinct cell groups, such as hepatocytes[45].

The therapeutic eminence index represents the amount of research that has advanced into clinical trials in the last 10 years, based on the Macrin *et al*[46] study (Figure 3). The eminent sources of adult MSCs are ordered following their therapeutic eminence index and are presented as follows: UC is the most eminent, then comes the placenta, AD, endometrium, dental pulp, and dermis successively, and the least eminent sources are amniotic fluid, synovium, and breast milk. Moreover, the cell types into which the isolated MSCs can differentiate vary, ranging from neurons and enterocytes to osteocytes and chondrocytes[47], *etc*. Among the eminent MSCs, three primary sources are capable of treating liver disease, namely the BM-MSCs, UC-MSCs, and AD-MSCs. Usually, MSCs derived from these sources express no signiﬁcant differences concerning the morphology and immune phenotype[47].

According to the research by Liu *et al*[48], the choice of MSCs should be related to the function and repair potentiality of the liver. Therefore, BM was selected as the best source compared to the three most capable sources to treat liver diseases. Accordingly, we decided to concentrate on BM-derived MSCs; as promising as this therapy can be, there are still many aspects of this therapy that need to be investigated.

***Identification of BM-MSCs***

As presented in Figure 4, the BM consists of two different cell lineages: the hematopoietic tissue cells and the associated stromal cells[49]. BM contains more than one stem cell population, and these include: (1) hematopoietic stem cells and endothelial progenitor cells (EPCs) obtained through flow cytometric cell sorting (known as FACS) according to cell surface markers; (2) side population cells present in the subpopulation as side scatters on FACS plot, owing to their ability to efflux Hoechst 33342 dye; (3) MSCs; and (4) multipotent adult progenitor cells, which are derived through the characterization of adherent cell populations.

Isolation and expansion of BM-MSCs involve aspiration of the iliac crest followed by separation of the mononuclear cell fraction by density-gradient centrifugation and plating for expansion. BM-MSCs can differentiate into ectodermal cell lineages that include neurons, endodermal cell lineages, such as hepatocytes[50], and mesodermal lineages, such as myocytes, chondrocytes, osteocytes, and adipocytes[51]. Considering this differentiation capacity, several possible applications of BM-MSCs have been suggested, tested, and studied[46].

There is a presence of pluripotency markers in BM-MSCs, suggesting that they can differentiate into cell lineages of all three germ layers. These surface marker expression levels and transcription factors play a significant role in distinguishing the stem cell populations[46]. Besides the regenerative and differentiation potentials of MSCs, the immunosuppressive and immunomodulatory properties are critical to their use in cellular therapy[52].

The potential contribution of BM-MSCs to liver fibrosis is presented in Figure 5. Each of the presented elements is a different mechanism that has a specific role that can alleviate liver fibrosis, such as the higher differentiation of AFP, CK18, and CK19, the activation of HSCs, and the higher mobility of KCs. The most dominant axis seems to be transdifferentiation to a collagen-producing myofibroblast cell population. However, other factors can also show a potential contribution to liver fibrosis.

BM-MSCs are known to express the MHC class I antigen but not the MHC class II antigen[53,54]. The coculture of BM-MSCs and HSCs inhibited the proliferation of HSCs and promoted cell apoptosis of HSCs through downregulating the E3 ligase S phase kinase associated protein 2 level, attenuating ubiquitination and increasing the stability of p27[55]. Moreover, BM-MSCs produce various growth factors and cytokines with anti-inflammatory effects *in vitro* and *in vivo* to inverse the fibrotic liver state. As transplantation of MSCs upsurges, the serum levels of vascular endothelial growth factor(VEGF), hepatocyte growth factor (HGF), IL-10, and MMP-9 increase in injured livers[56].

BM-MSCs attenuate hepatic fibrosis *in vivo* by decreased serum levels of collagen I, collagen IV, type III procollagen, hyaluronic acid, laminin, downregulated liver collagen proportionate area, hepatic hydroxyproline, and liver α-smooth muscle actin (SMA). This improvement is accompanied by reduced hepatic levels of TGF-β1, decreased expression of serum TGF-β1, Smad3, and Smad4 but increased Smad7 expression[57,58]. BM-MSCs significantly ameliorate liver fibrosis in mice *via* stimulation of interferon-γ and inhibition of lymphocyte proliferation; the BM-MSCs also significantly decreased the number of IL-17 producing Th17 cells and the serum level of inflammatory IL-17 while increasing the serum levels of kynurenine, immunosuppressive IL-10, indoleamine 2,3-dioxygenase, and a number of CD4+ IL-10+ T cells to attenuate liver fibrosis[59].

BM-MSCs are also confronting various challenges to reach clinical application requirements, such as the highly invasive donation procedure, the decline in MSC number and differentiation potential with increasing age, demands of a large number of cells for therapy, heterogeneic character of cell quality, low survival ability after transplantation, the weakening of MSC capacities in two-dimensional (2D) culture, and unclear mechanism of MSC function for disease therapy. An essential need for MSC therapy is to produce enough high-quality MSCs *in vitro* to meet clinical demand.

**PRE-TRANSPLANTATION STEPS**

***Culture***

As explained in Figure 6, different methods are used to culture stem cells; the general way is to culture MSCs in 2D dishes as a monolayer for fast expansion. This method conjures changes in MSCs, including cellular senescence, immunogenicity, losses of their stemness properties and paracrine activity, genetic expression of cells, and altered inner structure of cells[60,61]. The second way is the three-dimensional (3D) culture, which artificially creates an environment in which cells can interact or grow with their surroundings in all three dimensions. Thus, 3D culture is regarded as a more suitable and closer physiological microenvironment for cell growth[62,63]. There are numerous 3D culture methods developed to form MSC spheroids, such as hanging-drop, magnetic levitation, chitosan membrane culture, microgravity bioreactor, and rotating culture[1,64]. These methods provide cells with a suspension culture condition where the 3D spheroids were formed mainly relying on cell-cell adhesion and interaction that promoted the self-assembly tendency of MSCs.

There are two main types of spheroid used for the 3D culture. The first of these is initially formed and derived from the aggregation of many individual cells and is named multiple cells-derived spheroid (MCDS). Growing evidence has shown that, in comparison to 2D culture, 3D MCDS culture enhances the characteristics of MSCs on cell survival, factor secretion, stemness maintenance, migration, and antisenescence *in vitro* and improves the capacities of anti-inflammation, angiogenesis, tissue repair, and regeneration *in vivo*[65,66]. However, despite the many advantages reported, visible defects restrict the direct application of MCDS-cultured MSCs in the clinic. These include the heterogeneity of cell quality in the whole spheroid, the multitudinous presence of individual MSCs with distinct viabilities, and the large size of MCDS resulting in different distributions of nutrients, oxygen, and waste metabolism between the core and periphery of the spheroid; moreover, the cells in the core are subjected to hostile metabolic stresses and tend to undergo apoptosis[67]. The large size (diameter > 100 μm) makes MCDSs unable to be directly injected into the body, as it poses risk of blood vessel blockage. So, the MCDSs generally must be dissociated into single cells by an enzymatic process before vein injection, but this affects the cells by causing damage and impairing viability[68].

The second type of spheroid is formed through a single cell-derived sphere (SCDS), based on the report by Qiao *et al*[69]. This formation can enhance the effectiveness of UC-MSCs thereby optimizing the quality of MSCs to meet the demand of the clinical application. *In vitro* and *in vivo* results have indicated that compared to 2D and MCDS cultures SCDS culture possesses some advantages for MSCs optimization, such as in cell stemness properties, survival ability, and therapeutic potential. However, despite this, there are still some questions that need to be explored further in the future; in particular, these questions involve the effects of SCDS culture on immunomodulatory capacities, inflammatory response, paracrine capacities, and cellular metabolism. Whether SCDS culture could markedly optimize BM-MSCs for potentially meeting the demand for clinical application also remains an unanswered question. In general, after cell transplantation, only a small number of MSCs migrate to injured tissues, so various studies have investigated effective strategies for improving the survival rate and activity of MSCs to treat liver fibrosis.

***Strategies to improve MSCs efficiency***

BM-MSCs have limited viability, with as low as < 1% of transplanted cells predicated to survive. Inflexibility of the microenvironment encountered upon transplantation may be the cause[70].Various strategies have been developed and implemented to improve cell therapy. In this section, we will focus on: genetic engineering and the preconditioning used during the culture phase; tissue engineering used on a 3D matrix and involving signaling molecules; and cell-free therapy achieved through the use of exomes (Ex) and microvesicles (MVs) (Figure 7).

**Genetic engineering:** BM-MSCs have also been genetically engineered to overexpress the desired gene to improve their therapeutic efficacy further. They can be used for the targeted delivery of therapeutic gene products as gene therapy. The genes capable of manipulation could be genes encoding receptors, growth factors, and cytokines. Genetically-engineered BM-MSCs have been applied as treatment to a range of genetic and acquired diseases. Genetic modification of BM-MSCs improves their therapeutic potential by enhancing various cellular features, like endurance and survival of the transplanted BM-MSC, angiogenesis, differentiation, homing, and anti-inflammatory effects[71].

This strategy investigated approaches to promote the expression of proteins involved in the homing of donor cells[72]. MSCs express low levels of molecules, including the homing factor stromal cell-derived factor-1 (SDF-1) and chemokine receptors[73]. Genetic manipulation of prosurvival or antiapoptosis genes have been shown to increase BM-MSC survival *in vivo*[74]. Through modulation of cellular networks, microRNAs can regulate mRNAs, including those involved in cell survival. MicroRNA overexpression can enhance BM-MSC survival[75]. Nonetheless, this strategy presents many risks, including carcinogenesis, that should be carefully considered when applying genetic manipulations.

**Tissue engineering:** Strategies that allow for BM-MSC homing and adaptation in the liver before initiating their regeneration will help improve cell survival. Several approaches have been investigated, involving coculture and the development of 3D systems that can involve a scaffold-based or scaffold-free system[76,77]. Cells grown in 3D systems would behave more like cells *in vivo* and could be implanted directly. Numerous synthetic polymers as well as natural materials have been assessed for their ability to raise the expression of hepatocyte-specific genes in BM-MSCs through hepatic differentiation[78]. The most significant performance effect was observed when a 1:5 ratio of BM-MSCs to hepatocytes was used both *in vitro* and *in vivo*[79]. Decellularized tissue is another system in use for tissue engineering; the decellularized liver tissue forms an ECM scaffold, improving MSC engraftment by offering a more physiological environment[80].

**Preconditioning:** Priming methods avoid genetic and chemical modifications entirely by altering culture conditions to influence gene expression[81]. These methods have been used to improve the tethering, activation, and transmigration steps of systemic homing. Preconditioning improves the survival signals and resistance of MSCs against stress and insults in the pathological environment[82]. In the preconditioning process, BM-MSCs can be pretreated or exposed to a sublethal dose of various insults, such as apoptotic cascade activation, hypoxia, toxins, ROS, inflammatory response, autophagy, and many others. Furthermore, preconditioning can enhance cell survival following the transplantation because it considerably induces therapeutic benefits of BM-MSCs by increasing the potential of cell differentiation and its paracrine protective effect, improving migration and homing of BM-MSCs to the lesion site, increasing regenerative and repair potentials, and suppressing inflammatory and immune responses that occur after transplantation[83]. Many preconditioning strategies involve exposing cells to a physical or an environmental shock and/or pharmacological modulators of targeted molecules[83,84]; the following three strategies exemplify such.

The first is a thermal preconditioning strategy carried out at 42 °C for 1-2 h before transplantation. It has been demonstrated to promote cell survival *in vivo*, and this outcome is related to the induction of heat shock protein expression, which inhibits apoptotic pathways[85,86].

The second is a hypoxic preconditioning strategy based upon the knowledge that hypoxia can promote defense mechanisms against oxidative stress. Hypoxia is a significant feature of MSCs; it plays a vital role in maintaining stem cell fate, self-renewal, and multipotency. Cultivating MSCs under hypoxia is an essential preconditioning step because it mimics the natural microenvironment of BM. The reaction of MSCs to hypoxic conditions is contradictory, however, indicating both damaging and ameliorating effects.

The third is a pharmacologic strategy to maintain cell viability after transplantation. This process includes the use of antioxidants and HIF-1α stabilizers to contribute to cell survival, as well as antimycin and mitochondrial electron transport inhibitors to promote cell survival by activating mitochondrial death pathways[87].

***Extracellular vesicles as a cell-free therapy***

Worries regarding the use of MSCs as a cellular therapeutic approach for the liver include their potential for aberrant differentiation, the peril of tumor formation, and the half-life of transplanted MSCs inadequate for tissue regeneration by differentiation[88]. To deal with these issues, the MSC secretome has been introduced as an acellular alternative therapy. Indeed, these soluble proteins or extracellular vesicles residing among the BM-MSCs and released by paracrine mechanisms could be a practical option and offer numerous advantages compared to the use of cellular therapies for liver diseases[89].

BM-MSCs can also release more elaborate structures, called extracellular vehicles (EVs)[90]. These EVs can be engineered to enhance anticipated activities or introduce specific effector molecules[91,92]. MSC-derived EVs were shown to improve hepatic injury and inflammation[93]. EVs from human MSCs preserve at least some of the immunomodulatory properties of the cells. MSC-derived induced pluripotent stem cell-EVs hold the EV characteristics that are usually obtained from tissue-derived MSCs, regardless of origin[94]. EVs could be a better therapeutic strategy because they characterize a physically different fraction and transport signals with more predictable effects. Although, the complex functions of EVs are still mostly undiscovered. Additional studies are needed to determine how long-circulating MSC-EVs survive after administration and what recognition pathways are used by the target cells.

***Choice of transplantation routes***

Many BM-MSC transplantation routes can be used for liver disease, in general. Some of the routes are direct, such as the portal vein and the hepatic artery; others are indirect routes, such as the peripheral vein, intrasplenic, intraperitoneal, BM reconstitution, and extra-corporeal liver assist device (Figure 8).

BM-MSC transplantation routes can affect the therapy’s potential because they conceptually represent the simplest method to improve MSCs homing by administrating the cells at or near the target tissue instead of infusing them through standard intravenous routes. It may seem intuitive that direct delivery of MSCs to a target tissue could result in higher retention[95].

There are conflicting data about the engraftment of transplanted BM-MSCs, and some concerns around the fibrogenic potential have been raised. Unwanted effects may depend on the route and dose of BM-MSC infusion[96,97]. Different routes can be used to transplant BM-MSCs, such as intravenous, intraperitoneal, intrahepatic, intrasplenic, or portal vein injection, but the effectiveness varies depending on the injection route. The peripheral vein is the most common transplantation route followed by the hepatic artery, intrasplenic, intrahepatic and portal vein injection. It has been shown that BM-MSCs administered through the peripheral vein migrate well into the liver parenchyma in chronic injury *in vivo*. Simultaneously, limited BM-MSC engraftment has been observed in an acute injury environment[98].

Furthermore, BM-MSCs endured in liver tissues when injected through the intrahepatic artery, indicating that BM-MSCs were present without differentiating into hepatocytes. Moreover, the intraportal infusion was found to be more efficient than the peripheral route in clinical trials. However, direct approaches, such as *via* the portal vein or hepatic artery, carry a risk of portal hypertensive bleeding following cell injection[99]. Generally, the lines of evidence provided by most of these clinical studies have been lacking.

**Efficiency of BM-MSCs for liver fibrosis *in vivo***

Several *in vivo* studies have continued to prove the efficiency of BM-MSCs in attenuating liver fibrosis induced by tioacetamide or carbon tetrachloride. These studies have investigated the efficiency and role of MSCs in liver fibrosis to elucidate the mechanism underlying the mobilization and function of BM-MSCs.

Mehrabani *et al*[100] investigated the regenerative effect of BM-MSCs in a rat model of liver fibrosis induced by tioacetamide. The study demonstrated that BM-MSCs could open a new window and be a therapy of choice in the amelioration of liver fibrosis because it alleviated liver fibrosis through the antifibrotic potential of BM-MSCs. The paracrine and endocrine functions of BM-MSCs also underlay the efficacy of these cells in the amelioration of liver damage through reducing inflammatory cells in the hepatic tissue and decreasing the alanine aminotransferase level.

Another study investigated the link between natural killer cells and liver fibrosis and their link to regenerative medicine. It was found that BM-MSCs alleviated liver fibrosis through suppressing the inflammatory response and the local proinflammatory cytokines. A significant increase in intrahepatic natural killer cells was also noted upon BM-MSC treatment[101]. BM-MSCs attenuate liver ﬁbrosis by decreasing serum levels of the inﬂammatory cytokine IL-17, increasing the immunosuppressive cytokine IL-10 and the related factors indoleamine 2,3-dioxygenase and kynurenine, reducing the number of IL-17-producing Th17 cells, and expanding the percentage of CD4+ IL-10+ T cells[59].

The BM-MSCs have also been shown to improve thioacetamide-induced liver fibrosis in rats by remolding the collagen ﬁbers, which could be lysed by MMPs, namely MMP-2-mediated degradation of the ECM. PKH26-labeled BM-MSCs were seeded into liver tissue and found to differentiate into healthy cells replacing the damaged ones with either hepatocytes or cholangiocytes. The reduction in α-SMA expression that was observed reﬂected a diminution in the number of activated HSCs[102].

BM-MSCs might play an immunomodulatory role in treating liver fibrosis through the down-regulation of IL-17A, affecting the IL-6/STAT3 signaling pathway. It was noted that after the treatment there was modulation of the cytokine milieu and among the signal transducers, including a significant downregulation of the genes encoding cytokines IL-17A, IL-17RA, IL-17F, and IL-17RC. In accordance with the BM-MSC administration was a decline in IL-17, IL-2, and IL-6 serum proteins and downregulation in the IL-17A and IL-17RA proteins in liver tissue. The BM-MSC administration also resulted in downregulation of both *Stat3* mRNA expression and p-STAT3 protein as well as *Stat5a* gene expression and p-SMAD3 and TGF-βR2 proteins and elevated p-STAT5 protein[103].

It was also evidenced that the SDF-1α/CXCR4, which is essential among the chemotactic axis regulating MSC migration from BM to fibrotic liver, can attenuate liver damage and thus alleviate liver fibrosis[104]. That same study identified VEGF as the key cytokine that contributes to MSC proliferation. These results provide further evidence for the role of MSCs in liver fibrosis and help to elucidate the mechanism underlying MSC mobilization under the condition of carbon tetrachloride-induced liver injury (the model system used in the study).

Transplantation of stem cells, including BM-MSCs, has proven to be competent for repairing fibrotic livers. The underlying mechanism promotes hepatocyte transdifferentiation and hepatocyte proliferation while inhibiting activated hepatic stellate cells, upregulating the activity of MMPs, and promoting neovascularization in liver tissues[105].

Considering that BM-MSCs have demonstrated a strong proliferative ability, multilineage potential, and no ethical considerations for widespread application to repair various organ injuries, they are currently transplanted *in vivo* to reduce hepatocyte apoptosis and promote hepatocyte regeneration[106]. Thus, in this review, we focused on the *in vivo* research in the literature starting from the year 2015 to address these two main issues: (1) the therapeutic efficiency of BM-MSCs compared to other types of treatments; and (2) the possibility to enhance the therapeutic efficiency of BM-MSCs through various strategies.

***Therapeutic efficiency of BM-MSCs compared to other treatments and stem cell sources***

The therapeutic efficiency of BM-MSCs depends on various factors, but there remains a need to compare this efficiency to that of other treatments and other MSC sources. In Table 1[107-116], we present those studies in the literature that have compared BM-MSC efficiency to other existing therapies and other sources up to the year 2015.

We noted that compared to such standard treatments as resveratrol and silybum marianum the regenerative capabilities and resolution of hepatic fibrosis was higher for the BM-MSCs. Treatment with BM-MSCs enhanced the liver state more effectively than either of the two drugs. It also significantly decreased levels of alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, malondialdehyde, TNF-α, and CYP450 and increased levels of albumin, superoxide dismutase, glutathione, glutathione S-transferase, and catalase. BM-MSCs could also reestablish liver structure and function, ameliorating the toxicity of carbon tetrachloride and improving liver function tests[107].

In other cases, drug treatment with imatinib, simvastatin, and decorin was found to be more efficient when used concomitant to BM-MSCs. For example, with imatinib the single treatment and combination therapy significantly reduced serum levels of alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase and downregulated α-SMA, procollagen I, procollagen III, collagen IV, and laminin. However, in pathological observations the highest therapeutic potential was achieved with a combination of BM-MSCs and imatinib[108]. Also, compared to simvastatin and decorin the cotreatment exhibited better histological improvement than was achieved with simvastatin or decorin alone. The combination treatment also lowered the hydroxyproline content, decreased hepatic collagen distribution, and rescued liver function impairment. The upregulation of α-SMA, collagen-1, TGF-b1, and p-Smad3 was prevented by the administration of the cotreatment, which exerted strong protective effects against hepatic fibrosis[109,110].

Depending on the source, the efficiency of MSCs differ; for instance, compared to human UC CD34+ cells, both the CD34+ cells and BM-MSCs have the same efficacy in significantly reducing TNF-α. Nevertheless, concerning liver function and gene expression, the UC CD34+ cells were more efficient in elevating albumin and reducing alanine aminotransferase concentrations and gene expression of collagen Iα, *TGF-β1*, *α-SMA*, albumin, and *MMP-9*. Thus, human UC CD34+ stem cells were deemed more efficient than the BM-MSCs[111].

While the UC-MSCs present similar effectiveness to BM-MSCs, levels were also compared to UC-EPCs and AD-MSCs. The UC-EPCs showed higher *MMP-2* and VEGF gene expression than BM-MSCs. Moreover, the UC-EPCs were more effective than BM-MSCs in increasing gene expression of *HGF*, *α-SMA*, and *Ki-67*. The UC-EPCs also showed significantly higher TGF-β than BM-MSCs[112]. Comparison of BM-MSCs and AD-MSCs showed them to be similarly efficient at attenuating liver fibrosis, both using a mechanism that involves inhibiting the activation and proliferation of HSCs and boosting apoptosis of HSCs. The AD-MSCs may be a better candidate than BM-MSCs for cell-based therapy to treat liver fibrosis because they improved the anti-inflammatory and antifibrotic effects to a slightly greater extent than the BM-MSCs, they are easier to prepare, and they are more effective at inhibiting HSC proliferation and apoptosis in the coculture system. However, the slight improvement in anti-inflammatory and antifibrotic effects did not reach the threshold of statistically significant difference[113,114].

The transplantation route also impacts BM-MSC competence. This is not the case for all though, as there are no notable differences in the impact from portal and tail vein injections. The former involves different procollagen gene expression than the latter; nevertheless, the liver serum markers and liver histology classification show no differences postinjection. Remarkably, there are also no differences in treatment effects for those two administrations. When considering safety, though, BM-MSC transfusion *via* a peripheral vein is a safer potential method. In other cases, the impact results differ; for example, the intravenous route is remarkably more efficient than the intrasplenic one. Although both routes achieve a similar enhancement of liver function, the intravenous route provides greater reduction in cytokine gene expression levels (IL-1β, IL-6, and INF-γ)[115,116].

As a result, we note that although BM-MSCs are more efficient than other treatments, combination treatment with other therapies can itself become a strategy to enhance the therapeutic potential of BM-MSCs. We also want to point out that even though BM-MSCs are considered the most significant source of stem cells and are more efficient in some cases, there should be more studies to consider the potential of other sources potential. Lastly, many possible transplantation routes can affect the therapeutic impact of BM-MSCs on liver fibrosis, but we have observed a lack of studies that research the advantages and disadvantages of these routes.

***Possibility to enhance the therapeutic efficiency of BM-MSCs***

The therapeutic efficiency of BM-MSCs as a treatment for liver fibrosis is influenced by numerous factors including culture conditions, delivery route, number of infused cells, gene modification of MSCs, and other potential factors. Hence, we herein arrange and analyze the current evidence related to BM-MSC transplantation in liver fibrosis and summarize the strategies for promoting the therapeutic efficiency of BM-MSC transplantation. We expect to develop other strategies to improve BM-MSC activities *in vivo* to restore liver function and alleviate liver fibrosis. Based on Table 2[117-129], the overall strategies used have a positive therapeutic impact on liver fibrosis. Notable among the various strategies are preconditioning using autophagy regulation, microencapsulation, and preconditioned media.

BM-MSCs conditioned medium preparation provided a predominant therapeutic role in experimentally-induced chronic liver fibrosis as demonstrated by improved morphological, immunohistochemical, and biochemical measures[118]. Still, future studies should be carried out to further delineate the mechanisms underlying their action.

Cell-free therapy with BM-MSC-MVs and human BM-MSCs-Ex is another method by which the healing effect is enhanced as demonstrated by human BM-MSCs-Ex providing a meaningfully greater therapeutic effect than the human BM-MSCs. In fact, the human BM-MSCs-Ex effectively alleviated liver fibrosis as evidenced by reduced collagen accumulation, inhibition of inflammation, enhanced liver functionality, and increased hepatocyte regeneration. Besides, the administration of hBM-MSCs-Ex reduced liver fibrosis *via* inhibition of Wnt/β-catenin signaling to prevent HSC activation. Therefore, the use of hBM-MSCs-Ex presents a new and promising therapeutic strategy for hepatic disease in the clinical setting[122].

Adding to that, genetically-modified BM-MSCs expressing TIMP-1-short hairpin RNA or with human MMP-1 boosted the original effects of BM-MSCs through a mechanism that involved enhancing the antifibrotic potential as well as the anti-inflammatory and proangiogenic effects. Although BM-MSC administration reduced liver fibrosis, transplantation of the BM-MSCs/MMP-1 enhanced the reduction in liver fibrosis to a greater extent. Therapy with BMSCs/MMP-1 also reduced collagen content and suppressed activation of HSCs in the fibrotic liver, leading to the subsequent improvement of liver injury and fibrosis[126].

In other cases, such strategies as preconditioning with melatonin enhanced the homing and transplantation of the BM-MSCs. Remarkably, melatonin-BM-MSCs showed better therapeutic outcomes, likely facilitated through a mechanism involving the improvement of cell homing and better maintenance of the balance between matrix degradation and accumulating factors that had a high ability to home into the injured liver. This could be related to a higher percentage of glycogen storage but a lower percentage of collagen and lipid accumulation. On the other hand, this could be due to lower expressions of TGF-β1 and Bax, and lower content of serum alanine aminotransferase but higher expressions of MMPs and Bcl2[120].

Simultaneously, other strategies, such as MSCs expressing EPO promoted cell viability and strengthened their migration ability to damaged cells. As an example, compared to BM-MSCs EPO-MSC treatment was found to promote cell viability and migration of the BM-MSCs and to enhance the antiﬁbrotic efﬁcacy without inducing apoptosis[124]. This finding supported improving the efﬁciency of MSC transplantation as a potential therapeutic strategy for liver ﬁbrosis.

Overall, each strategy tackles specific aspects that can enhance the therapeutic potential of BM-MSCs, but there are no strategies that tackle several aspects at the same time. Therefore, there is a need to create strategies that can affect various aspects and mechanisms related to improving the potential of BM-MSCs as a therapy for liver fibrosis. Moreover, these strategies need to have sufficient safety, proficiency, and productivity features. It is also important to mention a deficiency in all types of strategies to enhance the therapy’s efficiency. Because there are many undiscovered and unclear aspects of the therapeutic mechanism of BM-MSCs for liver fibrosis, there is also room for new strategies to be discovered and researched.

***Limitations and further study***

This review successfully studied the recent advances in therapeutic efficiency of BM-MSCs for liver fibrosis, focusing on the preclinical *in vivo* experiments while mentioning the gaps that still exist within the field. However, this review remains limited because it focused mostly on preclinical studies performed on animals; although these studies targeted many aspects of the topic, different targets still need to be addressed. This review did not address clinical studies, but it is crucial to address all the concerns regarding long-term follow-up exams for humans. Only then may we draw solid conclusions on the therapeutic effects of BM-MSC transplantation on liver fibrosis. Ultimately, such additional work will also help to further improve the therapeutic effects of BM-MSC transplantation for liver fibrosis, enhancing the quality of life and prolonging patient survival time with liver fibrosis.

**CONCLUSION**

Various therapeutic methods are used to alleviate liver fibrosis; BM-MSCs are a promising therapy being investigated *in vivo*. This type of therapy has diverse advantages, including anti-inflammatory, self-renewal, and multipotency abilities. Thus, more and more studies are investigating the anti-inflammatory and immunomodulatory effects of BM-MSCs and focusing on comparing them with other stem cell sources and treatments to identify and develop an optimal treatment for the regression of liver fibrosis. Ongoing studies are focused on determining the different factors affecting the therapeutic efficiency of BM-MSCs, such as the transplantation route, where the portal vein route may be the optimum choice for restoring liver function in liver fibrosis, and the strategies used, including BM-MSC-based cell-free therapy and preconditioned, tissue-engineered, and genetic-engineered BM-MSC transplantation. These strategies have thus far presented promising results, but more research and experiments need to be done to find the optimum and most efficient strategy (or strategies) to enhance the therapeutic effect and be elevated to clinical trials.

**REFERENCES**

1 **Jiang B**, Yan L, Miao Z, Li E, Wong KH, Xu RH. Spheroidal formation preserves human stem cells for prolonged time under ambient conditions for facile storage and transportation. *Biomaterials* 2017; **133**: 275-286 [PMID: 28460350 DOI: 10.1016/j.biomaterials.2017.03.050]

2 **Kim G**, Eom YW, Baik SK, Shin Y, Lim YL, Kim MY, Kwon SO, Chang SJ. Therapeutic Effects of Mesenchymal Stem Cells for Patients with Chronic Liver Diseases: Systematic Review and Meta-analysis. *J Korean Med Sci* 2015; **30**: 1405-1415 [PMID: 26425036 DOI: 10.3346/jkms.2015.30.10.1405]

3 **Secunda R**, Vennila R, Mohanashankar AM, Rajasundari M, Jeswanth S, Surendran R. Isolation, expansion and characterisation of mesenchymal stem cells from human bone marrow, adipose tissue, umbilical cord blood and matrix: a comparative study. *Cytotechnology* 2015; **67**: 793-807 [PMID: 24798808 DOI: 10.1007/s10616-014-9718-z]

4 **Ji ST**, Kim H, Yun J, Chung JS, Kwon SM. Promising Therapeutic Strategies for Mesenchymal Stem Cell-Based Cardiovascular Regeneration: From Cell Priming to Tissue Engineering. *Stem Cells Int* 2017; **2017**: 3945403 [PMID: 28303152 DOI: 10.1155/2017/3945403]

5 **Bataller R**, Brenner DA. Liver fibrosis. *J Clin Invest* 2005; **115**: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]

6 **Ebrahimi H**, Naderian M, Sohrabpour AA. New Concepts on Pathogenesis and Diagnosis of Liver Fibrosis; A Review Article. *Middle East J Dig Dis* 2016; **8**: 166-178 [PMID: 27698966 DOI: 10.15171/mejdd.2016.29]

7 **Xu L**, Gong Y, Wang B, Shi K, Hou Y, Wang L, Lin Z, Han Y, Lu L, Chen D, Lin X, Zeng Q, Feng W, Chen Y. Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg/Th17 cells. *J Gastroenterol Hepatol* 2014; **29**: 1620-1628 [PMID: 24942592 DOI: 10.1111/jgh.12653]

8 **Sourianarayanane A**, Arikapudi S, McCullough AJ, Humar A. Nonalcoholic steatohepatitis recurrence and rate of fibrosis progression following liver transplantation. *Eur J Gastroenterol Hepatol* 2017; **29**: 481-487 [PMID: 28253211 DOI: 10.1097/MEG.0000000000000820]

9 **Sombetzki M**, Fuchs CD, Fickert P, Österreicher CH, Mueller M, Claudel T, Loebermann M, Engelmann R, Langner C, Sahin E, Schwinge D, Guenther ND, Schramm C, Mueller-Hilke B, Reisinger EC, Trauner M. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. *J Hepatol* 2015; **62**: 871-878 [PMID: 25463533 DOI: 10.1016/j.jhep.2014.11.020]

10 **Todorov T**, Balakrishnan P, Savov A, Socha P, Schmidt HH. Intragenic Deletions in ATP7B as an Unusual Molecular Genetics Mechanism of Wilson’s Disease Pathogenesis. *PLoS One* 2016; **11**: e0168372 [PMID: 27992490 DOI: 10.1371/journal.pone.0168372]

11 **Blachier M**, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. *J Hepatol* 2013; **58**: 593-608 [PMID: 23419824 DOI: 10.1016/j.jhep.2012.12.005]

12 **Schuppan D**, Ruehl M, Somasundaram R, Hahn EG. Matrix as a modulator of hepatic fibrogenesis. *Semin Liver Dis* 2001; **21**: 351-372 [PMID: 11586465 DOI: 10.1055/s-2001-17556]

13 **Bonis PA**, Friedman SL, Kaplan MM. Is liver fibrosis reversible? *N Engl J Med* 2001; **344**: 452-454 [PMID: 11172184 DOI: 10.1056/NEJM200102083440610]

14 **Shen X**, Cheng S, Peng Y, Song H, Li H. Attenuation of early liver fibrosis by herbal compound “Diwu Yanggan” through modulating the balance between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition. *BMC Complement Altern Med* 2014; **14**: 418 [PMID: 25345787 DOI: 10.1186/1472-6882-14-418]

15 **Friedman SL**. Mechanisms of hepatic fibrogenesis. *Gastroenterology* 2008; **134**: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]

16 **Pinzani M**. Liver fibrosis. *Springer Semin Immunopathol* 1999; **21**: 475-490 [PMID: 10945037 DOI: 10.1007/s002810000037]

17 **Benyon RC**, Iredale JP. Is liver fibrosis reversible? *Gut* 2000; **46**: 443-446 [PMID: 10716665 DOI: 10.1136/gut.46.4.443]

18 **Arthur MJ**. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. *Am J Physiol Gastrointest Liver Physiol* 2000; **279**: G245-G249 [PMID: 10915630 DOI: 10.1152/ajpgi.2000.279.2.G245]

19 **Gäbele E**, Brenner DA, Rippe RA. Liver fibrosis: signals leading to the amplification of the fibrogenic hepatic stellate cell. *Front Biosci* 2003; **8**: d69-d77 [PMID: 12456323 DOI: 10.2741/887]

20 **Milani S**, Herbst H, Schuppan D, Kim KY, Riecken EO, Stein H. Procollagen expression by nonparenchymal rat liver cells in experimental biliary fibrosis. *Gastroenterology* 1990; **98**: 175-184 [PMID: 2293576 DOI: 10.1016/0016-5085(90)91307-r]

21 **Marra F**. Hepatic stellate cells and the regulation of liver inflammation. *J Hepatol* 1999; **31**: 1120-1130 [PMID: 10604588 DOI: 10.1016/s0168-8278(99)80327-4]

22 **Lindquist JN**, Marzluff WF, Stefanovic B. Fibrogenesis. III. Posttranscriptional regulation of type I collagen. *Am J Physiol Gastrointest Liver Physiol* 2000; **279**: G471-G476 [PMID: 10960344 DOI: 10.1152/ajpgi.2000.279.3.G471]

23 **Higuchi H**, Gores GJ. Mechanisms of liver injury: an overview. *Curr Mol Med* 2003; **3**: 483-490 [PMID: 14527080 DOI: 10.2174/1566524033479528]

24 **Canbay A**, Friedman S, Gores GJ. Apoptosis: the nexus of liver injury and fibrosis. *Hepatology* 2004; **39**: 273-278 [PMID: 14767974 DOI: 10.1002/hep.20051]

25 **Viñas O**, Bataller R, Sancho-Bru P, Ginès P, Berenguer C, Enrich C, Nicolás JM, Ercilla G, Gallart T, Vives J, Arroyo V, Rodés J. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. *Hepatology* 2003; **38**: 919-929 [PMID: 14512879 DOI: 10.1053/jhep.2003.50392]

26 **Maher JJ**. Interactions between hepatic stellate cells and the immune system. *Semin Liver Dis* 2001; **21**: 417-426 [PMID: 11586469 DOI: 10.1055/s-2001-17555]

27 **Shi Z**, Wakil AE, Rockey DC. Strain-specific differences in mouse hepatic wound healing are mediated by divergent T helper cytokine responses. *Proc Natl Acad Sci USA* 1997; **94**: 10663-10668 [PMID: 9380692 DOI: 10.1073/pnas.94.20.10663]

28 **Naito M**, Hasegawa G, Ebe Y, Yamamoto T. Differentiation and function of Kupffer cells. *Med Electron Microsc* 2004; **37**: 16-28 [PMID: 15057601 DOI: 10.1007/s00795-003-0228-x]

29 **Thurman RG**. II. Alcoholic liver injury involves activation of Kupffer cells by endotoxin. *Am J Physiol* 1998; **275**: G605-G611 [PMID: 9756487 DOI: 10.1152/ajpgi.1998.275.4.G605]

30 **Gressner AM**, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. *Front Biosci* 2002; **7**: d793-d807 [PMID: 11897555]

31 **Olaso E**, Ikeda K, Eng FJ, Xu L, Wang LH, Lin HC, Friedman SL. DDR2 receptor promotes MMP-2-mediated proliferation and invasion by hepatic stellate cells. *J Clin Invest* 2001; **108**: 1369-1378 [PMID: 11696582 DOI: 10.1172/JCI12373]

32 **Hipp J**, Atala A. Sources of stem cells for regenerative medicine. *Stem Cell Rev* 2008; **4**: 3-11 [PMID: 18286392 DOI: 10.1007/s12015-008-9010-8]

33 **Gruber HE**, Deepe R, Hoelscher GL, Ingram JA, Norton HJ, Scannell B, Loeffler BJ, Zinchenko N, Hanley EN, Tapp H. Human adipose-derived mesenchymal stem cells: direction to a phenotype sharing similarities with the disc, gene expression profiling, and coculture with human annulus cells. *Tissue Eng Part A* 2010; **16**: 2843-2860 [PMID: 20408770 DOI: 10.1089/ten.TEA.2009.0709]

34 **Banas A**, Teratani T, Yamamoto Y, Tokuhara M, Takeshita F, Quinn G, Okochi H, Ochiya T. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. *Hepatology* 2007; **46**: 219-228 [PMID: 17596885 DOI: 10.1002/hep.21704]

35 **McElreavey KD**, Irvine AI, Ennis KT, McLean WH. Isolation, culture and characterisation of fibroblast-like cells derived from the Wharton’s jelly portion of human umbilical cord. *Biochem Soc Trans* 1991; **19**: 29S [PMID: 1709890 DOI: 10.1042/bst019029s]

36 **Tsai MS**, Hwang SM, Tsai YL, Cheng FC, Lee JL, Chang YJ. Clonal amniotic fluid-derived stem cells express characteristics of both mesenchymal and neural stem cells. *Biol Reprod* 2006; **74**: 545-551 [PMID: 16306422 DOI: 10.1095/biolreprod.105.046029]

37 **Yu X**, Wang N, Qiang R, Wan Q, Qin M, Chen S, Wang H. Human amniotic fluid stem cells possess the potential to differentiate into primordial follicle oocytes in vitro. *Biol Reprod* 2014; **90**: 73 [PMID: 24571984 DOI: 10.1095/biolreprod.113.112920]

38 **Hosseini SM**, Talaei-Khozani T, Sani M, Owrangi B. Differentiation of human breast-milk stem cells to neural stem cells and neurons. *Neurol Res Int* 2014; **2014**: 807896 [PMID: 25506428 DOI: 10.1155/2014/807896]

39 **Fan Y**, Chong YS, Choolani MA, Cregan MD, Chan JK. Unravelling the mystery of stem/progenitor cells in human breast milk. *PLoS One* 2010; **5**: e14421 [PMID: 21203434 DOI: 10.1371/journal.pone.0014421]

40 **Ogata Y**, Mabuchi Y, Yoshida M, Suto EG, Suzuki N, Muneta T, Sekiya I, Akazawa C. Purified Human Synovium Mesenchymal Stem Cells as a Good Resource for Cartilage Regeneration. *PLoS One* 2015; **10**: e0129096 [PMID: 26053045 DOI: 10.1371/journal.pone.0129096]

41 **Gnecchi M**, Melo LG. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. *Methods Mol Biol* 2009; **482**: 281-294 [PMID: 19089363 DOI: 10.1007/978-1-59745-060-7\_18]

42 **In ‘t Anker PS**, Scherjon SA, Kleijburg-van der Keur C, de Groot-Swings GM, Claas FH, Fibbe WE, Kanhai HH. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. *Stem Cells* 2004; **22**: 1338-1345 [PMID: 15579651 DOI: 10.1634/stemcells.2004-0058]

43 **Ponnaiyan D**, Bhat KM, Bhat GS. Comparison of immuno-phenotypes of stem cells from human dental pulp and periodontal ligament. *Int J Immunopathol Pharmacol* 2012; **25**: 127-134 [PMID: 22507325 DOI: 10.1177/039463201202500115]

44 **In ‘t Anker PS**, Noort WA, Scherjon SA, Kleijburg-van der Keur C, Kruisselbrink AB, van Bezooijen RL, Beekhuizen W, Willemze R, Kanhai HH, Fibbe WE. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. *Haematologica* 2003; **88**: 845-852 [PMID: 12935972]

45 **Lee KD**, Kuo TK, Whang-Peng J, Chung YF, Lin CT, Chou SH, Chen JR, Chen YP, Lee OK. In vitro hepatic differentiation of human mesenchymal stem cells. *Hepatology* 2004; **40**: 1275-1284 [PMID: 15562440 DOI: 10.1002/hep.20469]

46 **Macrin D**, Joseph JP, Pillai AA, Devi A. Eminent Sources of Adult Mesenchymal Stem Cells and Their Therapeutic Imminence. *Stem Cell Rev Rep* 2017; **13**: 741-756 [PMID: 28812219 DOI: 10.1007/s12015-017-9759-8]

47 **Kern S**, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. *Stem Cells* 2006; **24**: 1294-1301 [PMID: 16410387 DOI: 10.1634/stemcells.2005-0342]

48 **Liu WH**, Song FQ, Ren LN, Guo WQ, Wang T, Feng YX, Tang LJ, Li K. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. *J Cell Mol Med* 2015; **19**: 511-520 [PMID: 25534251 DOI: 10.1111/jcmm.12482]

49 **Bianco P**, Riminucci M, Gronthos S, Robey PG. Bone marrow stromal stem cells: nature, biology, and potential applications. *Stem Cells* 2001; **19**: 180-192 [PMID: 11359943 DOI: 10.1634/stemcells.19-3-180]

50 **Dueñas F**, Becerra V, Cortes Y, Vidal S, Sáenz L, Palomino J, De Los Reyes M, Peralta OA. Hepatogenic and neurogenic differentiation of bone marrow mesenchymal stem cells from abattoir-derived bovine fetuses. *BMC Vet Res* 2014; **10**: 154 [PMID: 25011474 DOI: 10.1186/1746-6148-10-154]

51 **Wagner W**, Feldmann RE Jr, Seckinger A, Maurer MH, Wein F, Blake J, Krause U, Kalenka A, Bürgers HF, Saffrich R, Wuchter P, Kuschinsky W, Ho AD. The heterogeneity of human mesenchymal stem cell preparations--evidence from simultaneous analysis of proteomes and transcriptomes. *Exp Hematol* 2006; **34**: 536-548 [PMID: 16569600 DOI: 10.1016/j.exphem.2006.01.002]

52 **Le Blanc K**, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler RM, Bacigalupo A, Fibbe W, Ringdén O; Developmental Committee of the European Group for Blood and Marrow Transplantation. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. *Lancet* 2008; **371**: 1579-1586 [PMID: 18468541 DOI: 10.1016/S0140-6736(08)60690-X]

53 **In ‘t Anker PS**, Scherjon SA, Kleijburg-van der Keur C, Noort WA, Claas FH, Willemze R, Fibbe WE, Kanhai HH. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. *Blood* 2003; **102**: 1548-1549 [PMID: 12900350 DOI: 10.1182/blood-2003-04-1291]

54 **Deuse T**, Stubbendorff M, Tang-Quan K, Phillips N, Kay MA, Eiermann T, Phan TT, Volk HD, Reichenspurner H, Robbins RC, Schrepfer S. Immunogenicity and immunomodulatory properties of umbilical cord lining mesenchymal stem cells. *Cell Transplant* 2011; **20**: 655-667 [PMID: 21054940 DOI: 10.3727/096368910X536473]

55 **Wang L**, Bai G, Chen F. Human bone marrow mesenchymal stem cells suppress the proliferation of hepatic stellate cells by inhibiting the ubiquitination of p27. *Biochem Cell Biol* 2017; **95**: 628-633 [PMID: 28746817 DOI: 10.1139/bcb-2017-0127]

56 **Li T**, Zhu J, Ma K, Liu N, Feng K, Li X, Wang S, Bie P. Autologous bone marrow-derived mesenchymal stem cell transplantation promotes liver regeneration after portal vein embolization in cirrhotic rats. *J Surg Res* 2013; **184**: 1161-1173 [PMID: 23809154 DOI: 10.1016/j.jss.2013.04.054]

57 **Jang YO**, Kim MY, Cho MY, Baik SK, Cho YZ, Kwon SO. Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model. *BMC Gastroenterol* 2014; **14**: 198 [PMID: 25425284 DOI: 10.1186/s12876-014-0198-6]

58 **Wang ZC**, Yang S, Huang JJ, Chen SL, Li QQ, Li Y. Effect of bone marrow mesenchymal stem cells on the Smad expression of hepatic fibrosis rats. *Asian Pac J Trop Med* 2014; **7**: 321-324 [PMID: 24507685 DOI: 10.1016/S1995-7645(14)60048-1]

59 **Milosavljevic N**, Gazdic M, Simovic Markovic B, Arsenijevic A, Nurkovic J, Dolicanin Z, Jovicic N, Jeftic I, Djonov V, Arsenijevic N, Lukic ML, Volarevic V. Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells - an experimental study. *Transpl Int* 2018; **31**: 102-115 [PMID: 28805262 DOI: 10.1111/tri.13023]

60 **Morikawa S**, Mabuchi Y, Kubota Y, Nagai Y, Niibe K, Hiratsu E, Suzuki S, Miyauchi-Hara C, Nagoshi N, Sunabori T, Shimmura S, Miyawaki A, Nakagawa T, Suda T, Okano H, Matsuzaki Y. Prospective identification, isolation, and systemic transplantation of multipotent mesenchymal stem cells in murine bone marrow. *J Exp Med* 2009; **206**: 2483-2496 [PMID: 19841085 DOI: 10.1084/jem.20091046]

61 **Toma C**, Wagner WR, Bowry S, Schwartz A, Villanueva F. Fate of culture-expanded mesenchymal stem cells in the microvasculature: *in vivo* observations of cell kinetics. *Circ Res* 2009; **104**: 398-402 [PMID: 19096027 DOI: 10.1161/CIRCRESAHA.108.187724]

62 **Antoni D**, Burckel H, Josset E, Noel G. Three-dimensional cell culture: a breakthrough in vivo. *Int J Mol Sci* 2015; **16**: 5517-5527 [PMID: 25768338 DOI: 10.3390/ijms16035517]

63 **Lee J**, Cuddihy MJ, Kotov NA. Three-dimensional cell culture matrices: state of the art. *Tissue Eng Part B Rev* 2008; **14**: 61-86 [PMID: 18454635 DOI: 10.1089/teb.2007.0150]

64 **Saleh FA**, Frith JE, Lee JA, Genever PG. Three-dimensional *in vitro* culture techniques for mesenchymal stem cells. *Methods Mol Biol* 2012; **916**: 31-45 [PMID: 22914931 DOI: 10.1007/978-1-61779-980-8\_4]

65 **Domnina A**, Novikova P, Obidina J, Fridlyanskaya I, Alekseenko L, Kozhukharova I, Lyublinskaya O, Zenin V, Nikolsky N. Human mesenchymal stem cells in spheroids improve fertility in model animals with damaged endometrium. *Stem Cell Res Ther* 2018; **9**: 50 [PMID: 29482664 DOI: 10.1186/s13287-018-0801-9]

66 **Lin RZ**, Chang HY. Recent advances in three-dimensional multicellular spheroid culture for biomedical research. *Biotechnol J* 2008; **3**: 1172-1184 [PMID: 18566957 DOI: 10.1002/biot.200700228]

67 **Tsai AC**, Liu Y, Yuan X, Ma T. Compaction, fusion, and functional activation of three-dimensional human mesenchymal stem cell aggregate. *Tissue Eng Part A* 2015; **21**: 1705-1719 [PMID: 25661745 DOI: 10.1089/ten.TEA.2014.0314]

68 **Seiberg M**, Siock P, Wisniewski S, Cauwenbergh G, Shapiro SS. The effects of trypsin on apoptosis, utriculi size, and skin elasticity in the Rhino mouse. *J Invest Dermatol* 1997; **109**: 370-376 [PMID: 9284107 DOI: 10.1111/1523-1747.ep12336244]

69 **Qiao Y**, Xu Z, Yu Y, Hou S, Geng J, Xiao T, Liang Y, Dong Q, Mei Y, Wang B, Qiao H, Dai J, Suo G. Single cell derived spheres of umbilical cord mesenchymal stem cells enhance cell stemness properties, survival ability and therapeutic potential on liver failure. *Biomaterials* 2020; **227**: 119573 [PMID: 31670080 DOI: 10.1016/j.biomaterials.2019.119573]

70 **Dhawan A**, Puppi J, Hughes RD, Mitry RR. Human hepatocyte transplantation: current experience and future challenges. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 288-298 [PMID: 20368738 DOI: 10.1038/nrgastro.2010.44]

71 **Hodgkinson CP**, Gomez JA, Mirotsou M, Dzau VJ. Genetic engineering of mesenchymal stem cells and its application in human disease therapy. *Hum Gene Ther* 2010; **21**: 1513-1526 [PMID: 20825283 DOI: 10.1089/hum.2010.165]

72 **Alfaifi M**, Eom YW, Newsome PN, Baik SK. Mesenchymal stromal cell therapy for liver diseases. *J Hepatol* 2018; **68**: 1272-1285 [PMID: 29425678 DOI: 10.1016/j.jhep.2018.01.030]

73 **Di Rocco G**, Gentile A, Antonini A, Ceradini F, Wu JC, Capogrossi MC, Toietta G. Enhanced healing of diabetic wounds by topical administration of adipose tissue-derived stromal cells overexpressing stromal-derived factor-1: biodistribution and engraftment analysis by bioluminescent imaging. *Stem Cells Int* 2010; **2011**: 304562 [PMID: 21234108 DOI: 10.4061/2011/304562]

74 **Mangi AA**, Noiseux N, Kong D, He H, Rezvani M, Ingwall JS, Dzau VJ. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. *Nat Med* 2003; **9**: 1195-1201 [PMID: 12910262 DOI: 10.1038/nm912]

75 **Xu J**, Huang Z, Lin L, Fu M, Gao Y, Shen Y, Zou Y, Sun A, Qian J, Ge J. miR-210 over-expression enhances mesenchymal stem cell survival in an oxidative stress environment through antioxidation and c-Met pathway activation. *Sci China Life Sci* 2014; **57**: 989-997 [PMID: 25168379 DOI: 10.1007/s11427-014-4725-z]

76 **Zeilinger K**, Freyer N, Damm G, Seehofer D, Knöspel F. Cell sources for in vitro human liver cell culture models. *Exp Biol Med (Maywood)* 2016; **241**: 1684-1698 [PMID: 27385595 DOI: 10.1177/1535370216657448]

77 **Godoy P**, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG. Recent advances in 2D and 3D *in vitro* systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME. *Arch Toxicol* 2013; **87**: 1315-1530 [PMID: 23974980 DOI: 10.1007/s00204-013-1078-5]

78 **Li J**, Tao R, Wu W, Cao H, Xin J, Li J, Guo J, Jiang L, Gao C, Demetriou AA, Farkas DL, Li L. 3D PLGA scaffolds improve differentiation and function of bone marrow mesenchymal stem cell-derived hepatocytes. *Stem Cells Dev* 2010; **19**: 1427-1436 [PMID: 20055663 DOI: 10.1089/scd.2009.0415]

79 **Liu M**, Yang J, Hu W, Zhang S, Wang Y. Superior performance of co-cultured mesenchymal stem cells and hepatocytes in poly(lactic acid-glycolic acid) scaffolds for the treatment of acute liver failure. *Biomed Mater* 2016; **11**: 015008 [PMID: 26836957 DOI: 10.1088/1748-6041/11/1/015008]

80 **Mazza G**, Rombouts K, Rennie Hall A, Urbani L, Vinh Luong T, Al-Akkad W, Longato L, Brown D, Maghsoudlou P, Dhillon AP, Fuller B, Davidson B, Moore K, Dhar D, De Coppi P, Malago M, Pinzani M. Decellularized human liver as a natural 3D-scaffold for liver bioengineering and transplantation. *Sci Rep* 2015; **5**: 13079 [PMID: 26248878 DOI: 10.1038/srep13079]

81 **Saeedi P**, Halabian R, Imani Fooladi AA. A revealing review of mesenchymal stem cells therapy, clinical perspectives and Modification strategies. *Stem Cell Investig* 2019; **6**: 34 [PMID: 31620481 DOI: 10.21037/sci.2019.08.11]

82 **Augustin M.** Preconditioning Methods in Cell Therapy of the Heart. Conference Proceedings, 2012 Oct 12; Helsingin yliopisto. Available from: http://hdl.handle.net/10138/36906

83 **Yu SP**, Wei Z, Wei L. Preconditioning strategy in stem cell transplantation therapy. *Transl Stroke Res* 2013; **4**: 76-88 [PMID: 23914259 DOI: 10.1007/s12975-012-0251-0]

84 **Haider HKh**, Ashraf M. Preconditioning and stem cell survival. *J Cardiovasc Transl Res* 2010; **3**: 89-102 [PMID: 20560023 DOI: 10.1007/s12265-009-9161-2]

85 **Feng Y**, Huang W, Meng W, Jegga AG, Wang Y, Cai W, Kim HW, Pasha Z, Wen Z, Rao F, Modi RM, Yu X, Ashraf M. Heat shock improves Sca-1+ stem cell survival and directs ischemic cardiomyocytes toward a prosurvival phenotype *via* exosomal transfer: a critical role for HSF1/miR-34a/HSP70 pathway. *Stem Cells* 2014; **32**: 462-472 [PMID: 24123326 DOI: 10.1002/stem.1571]

86 **Qiao PF**, Yao L, Zhang XC, Li GD, Wu DQ. Heat shock pretreatment improves stem cell repair following ischemia-reperfusion injury *via* autophagy. *World J Gastroenterol* 2015; **21**: 12822-12834 [PMID: 26668506 DOI: 10.3748/wjg.v21.i45.12822]

87 **Carrière A**, Ebrahimian TG, Dehez S, Augé N, Joffre C, André M, Arnal S, Duriez M, Barreau C, Arnaud E, Fernandez Y, Planat-Benard V, Lévy B, Pénicaud L, Silvestre JS, Casteilla L. Preconditioning by mitochondrial reactive oxygen species improves the proangiogenic potential of adipose-derived cells-based therapy. *Arterioscler Thromb Vasc Biol* 2009; **29**: 1093-1099 [PMID: 19423864 DOI: 10.1161/ATVBAHA.109.188318]

88 **Volarevic V**, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M, Stojkovic M. Ethical and Safety Issues of Stem Cell-Based Therapy. *Int J Med Sci* 2018; **15**: 36-45 [PMID: 29333086 DOI: 10.7150/ijms.21666]

89 **Eggenhofer E**, Luk F, Dahlke MH, Hoogduijn MJ. The life and fate of mesenchymal stem cells. *Front Immunol* 2014; **5**: 148 [PMID: 24904568 DOI: 10.3389/fimmu.2014.00148]

90 **Camussi G**, Deregibus MC, Cantaluppi V. Role of stem-cell-derived microvesicles in the paracrine action of stem cells. *Biochem Soc Trans* 2013; **41**: 283-287 [PMID: 23356298 DOI: 10.1042/BST20120192]

91 **Koppers-Lalic D**, Hogenboom MM, Middeldorp JM, Pegtel DM. Virus-modified exosomes for targeted RNA delivery; a new approach in nanomedicine. *Adv Drug Deliv Rev* 2013; **65**: 348-356 [PMID: 22820525 DOI: 10.1016/j.addr.2012.07.006]

92 **Kooijmans SAA**, Schiffelers RM, Zarovni N, Vago R. Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment. *Pharmacol Res* 2016; **111**: 487-500 [PMID: 27394168 DOI: 10.1016/j.phrs.2016.07.006]

93 **Li T**, Yan Y, Wang B, Qian H, Zhang X, Shen L, Wang M, Zhou Y, Zhu W, Li W, Xu W. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. *Stem Cells Dev* 2013; **22**: 845-854 [PMID: 23002959 DOI: 10.1089/scd.2012.0395]

94 **Nong K**, Wang W, Niu X, Hu B, Ma C, Bai Y, Wu B, Wang Y, Ai K. Hepatoprotective effect of exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats. *Cytotherapy* 2016; **18**: 1548-1559 [PMID: 27592404 DOI: 10.1016/j.jcyt.2016.08.002]

95 **Ullah M**, Liu DD, Thakor AS. Mesenchymal Stromal Cell Homing: Mechanisms and Strategies for Improvement. *iScience* 2019; **15**: 421-438 [PMID: 31121468 DOI: 10.1016/j.isci.2019.05.004]

96 **Meier RP**, Müller YD, Morel P, Gonelle-Gispert C, Bühler LH. Transplantation of mesenchymal stem cells for the treatment of liver diseases, is there enough evidence? *Stem Cell Res* 2013; **11**: 1348-1364 [PMID: 24090934 DOI: 10.1016/j.scr.2013.08.011]

97 **di Bonzo LV**, Ferrero I, Cravanzola C, Mareschi K, Rustichell D, Novo E, Sanavio F, Cannito S, Zamara E, Bertero M, Davit A, Francica S, Novelli F, Colombatto S, Fagioli F, Parola M. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation *versus* profibrogenic potential. *Gut* 2008; **57**: 223-231 [PMID: 17639088 DOI: 10.1136/gut.2006.111617]

98 **Amer ME**, El-Sayed SZ, El-Kheir WA, Gabr H, Gomaa AA, El-Noomani N, Hegazy M. Clinical and laboratory evaluation of patients with end-stage liver cell failure injected with bone marrow-derived hepatocyte-like cells. *Eur J Gastroenterol Hepatol* 2011; **23**: 936-941 [PMID: 21900788 DOI: 10.1097/MEG.0b013e3283488b00]

99 **Salama H**, Zekri AR, Zern M, Bahnassy A, Loutfy S, Shalaby S, Vigen C, Burke W, Mostafa M, Medhat E, Alfi O, Huttinger E. Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases. *Cell Transplant* 2010; **19**: 1475-1486 [PMID: 20587151 DOI: 10.3727/096368910X514314]

100 **Mehrabani D**, Khajehahmadi Z, Tajik P, Tamadon A, Rahmanifar F, Ashraf M, Tanideh N, Zare S. Regenerative Effect of Bone Marrow-derived Mesenchymal Stem Cells in Thioacetamide-induced Liver Fibrosis of Rats. *Arch Razi Inst* 2019; **74**: 279-286 [PMID: 31592593 DOI: 10.22092/ari.2018.110029.1120]

101 **Duman DG**, Zibandeh N, Ugurlu MU, Celikel C, Akkoc T, Banzragch M, Genc D, Ozdogan O, Akkoc T. Mesenchymal stem cells suppress hepatic fibrosis accompanied by expanded intrahepatic natural killer cells in rat fibrosis model. *Mol Biol Rep* 2019; **46**: 2997-3008 [PMID: 30850965 DOI: 10.1007/s11033-019-04736-4]

102 **Mansour FAA,** Shaheed I, Hassan NRA. Use of Bone Marrow-Derived Mesenchymal Stem Cells in Improving Thioacetamide Induced Liver Fibrosis in Rats. In: Polychroniadis E, Oral A, Ozer M, 2nd ed. International Multidisciplinary Microscopy and Microanalysis Congress. Springer Proceedings in Physics, 2015; 164. Springer, Cham [DOI: 10.1007/978-3-319-16919-4\_29]

103 **Farouk S**, Sabet S, Abu Zahra FA, El-Ghor AA. Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis. *PLoS One* 2018; **13**: e0206130 [PMID: 30346985 DOI: 10.1371/journal.pone.0206130]

104 **Liu Y**, Yang X, Jing Y, Zhang S, Zong C, Jiang J, Sun K, Li R, Gao L, Zhao X, Wu D, Shi Y, Han Z, Wei L. Contribution and Mobilization of Mesenchymal Stem Cells in a mouse model of carbon tetrachloride-induced liver fibrosis. *Sci Rep* 2015; **5**: 17762 [PMID: 26643997 DOI: 10.1038/srep17762]

105 **Vainshtein JM**, Kabarriti R, Mehta KJ, Roy-Chowdhury J, Guha C. Bone marrow-derived stromal cell therapy in cirrhosis: clinical evidence, cellular mechanisms, and implications for the treatment of hepatocellular carcinoma. *Int J Radiat Oncol Biol Phys* 2014; **89**: 786-803 [PMID: 24969793 DOI: 10.1016/j.ijrobp.2014.02.017]

106 **Hu C**, Li L. In Vitro and In Vivo Hepatic Differentiation of Adult Somatic Stem Cells and Extraembryonic Stem Cells for Treating End Stage Liver Diseases. *Stem Cells Int* 2015; **2015**: 871972 [PMID: 26347063 DOI: 10.1155/2015/871972]

107 **Khalil MR**, El-Demerdash RS, Elminshawy HH, Mehanna ET, Mesbah NM, Abo-Elmatty DM. Therapeutic effect of bone marrow mesenchymal stem cells in a rat model of carbon tetrachloride induced liver fibrosis. *Biomed J* 2020 [PMID: 32389821 DOI: 10.1016/j.bj.2020.04.011]

108 **Mazhari S**, Gitiara A, Baghaei K, Hatami B, Rad RE, Asadirad A, Joharchi K, Tokhanbigli S, Hashemi SM, Łos MJ, Aghdaei HA, Zali MR, Ghavami S. Therapeutic potential of bone marrow-derived mesenchymal stem cells and imatinib in a rat model of liver fibrosis. *Eur J Pharmacol* 2020; **882**: 173263 [PMID: 32535098 DOI: 10.1016/j.ejphar.2020.173263]

109 **Jang YO**, Kim SH, Cho MY, Kim KS, Park KS, Cha SK, Kim MY, Chang SJ, Baik SK. Synergistic effects of simvastatin and bone marrow-derived mesenchymal stem cells on hepatic fibrosis. *Biochem Biophys Res Commun* 2018; **497**: 264-271 [PMID: 29428718 DOI: 10.1016/j.bbrc.2018.02.067]

110 **Jang YO**, Cho MY, Yun CO, Baik SK, Park KS, Cha SK, Chang SJ, Kim MY, Lim YL, Kwon SO. Effect of Function-Enhanced Mesenchymal Stem Cells Infected With Decorin-Expressing Adenovirus on Hepatic Fibrosis. *Stem Cells Transl Med* 2016; **5**: 1247-1256 [PMID: 27365486 DOI: 10.5966/sctm.2015-0323]

111 **Sayyed HG**, Osama A, Idriss NK, Sabry D, Abdelrhim AS, Bakry R. Comparison of the therapeutic effectiveness of human CD34+ and rat bone marrow mesenchymal stem cells on improvement of experimental liver fibrosis in Wistar rats. *Int J Physiol Pathophysiol Pharmacol* 2016; **8**: 128-139 [PMID: 27785340]

112 **Abdelgwad M**, Ewaiss M, Sabry D, Khalifa WA, Altaib ZM, Alhelf M. Comparative study on effect of mesenchymal stem cells and endothelial progenitor cells on treatment of experimental CCL4-induced liver fibrosis. *Arch Physiol Biochem* 2020; 1-10 [PMID: 32374186 DOI: 10.1080/13813455.2020.1752256]

113 **Rengasamy M**, Singh G, Fakharuzi NA, Siddikuzzaman, Balasubramanian S, Swamynathan P, Thej C, Sasidharan G, Gupta PK, Das AK, Rahman AZA, Fakiruddin KS, Nian LM, Zakaria Z, Majumdar AS. Transplantation of human bone marrow mesenchymal stromal cells reduces liver fibrosis more effectively than Wharton’s jelly mesenchymal stromal cells. *Stem Cell Res Ther* 2017; **8**: 143 [PMID: 28610623 DOI: 10.1186/s13287-017-0595-1]

114 **Hao T**, Chen J, Zhi S, Zhang Q, Chen G, Yu F. Comparison of bone marrow-vs. adipose tissue-derived mesenchymal stem cells for attenuating liver fibrosis. *Exp Ther Med* 2017; **14**: 5956-5964 [PMID: 29285145 DOI: 10.3892/etm.2017.5333]

115 **Idriss NK**, Sayyed HG, Osama A, Sabry D. Treatment Efficiency of Different Routes of Bone Marrow-Derived Mesenchymal Stem Cell Injection in Rat Liver Fibrosis Model. *Cell Physiol Biochem* 2018; **48**: 2161-2171 [PMID: 30114694 DOI: 10.1159/000492558]

116 **Truong NH**, Nguyen NH, Le TV, Vu NB, Huynh N, Nguyen TV, Le HM, Phan NK, Pham PV. Comparison of the Treatment Efficiency of Bone Marrow-Derived Mesenchymal Stem Cell Transplantation *via* Tail and Portal Veins in CCl4-Induced Mouse Liver Fibrosis. *Stem Cells Int* 2016; **2016**: 5720413 [PMID: 26839564 DOI: 10.1155/2016/5720413]

117 **Wang HY**, Li C, Liu WH, Deng FM, Ma Y, Guo LN, Kong H, Hu KA, Liu Q, Wu J, Sun J, Liu YL. Autophagy inhibition *via* Becn1 downregulation improves the mesenchymal stem cells antifibrotic potential in experimental liver fibrosis. *J Cell Physiol* 2020; **235**: 2722-2737 [PMID: 31508820 DOI: 10.1002/jcp.29176]

118 **Abdel Aal S,** Abdelrahman S, Raafat N. Comparative therapeutic effects of mesenchymal stem cells *vs* their conditioned media in alleviation of CCL4-induced liver fibrosis in rats: Histological and biochemical study. *J Med Histol* 2019; **3**: 1-20 [DOI: 10.21608/jmh.2019.10310.1051]

119 **Mortezaee K**, Pasbakhsh P, Ragerdi Kashani I, Sabbaghziarani F, Omidi A, Zendedel A, Ghasemi S, Dehpour AR. Melatonin Pretreatment Enhances the Homing of Bone Marrow-derived Mesenchymal Stem Cells Following Transplantation in a Rat Model of Liver Fibrosis. *Iran Biomed J* 2016; **20**: 207-216 [PMID: 27130910 DOI: 10.7508/ibj.2016.04.004]

120 **Mortezaee K**, Khanlarkhani N, Sabbaghziarani F, Nekoonam S, Majidpoor J, Hosseini A, Pasbakhsh P, Kashani IR, Zendedel A. Preconditioning with melatonin improves therapeutic outcomes of bone marrow-derived mesenchymal stem cells in targeting liver fibrosis induced by CCl4. *Cell Tissue Res* 2017; **369**: 303-312 [PMID: 28413861 DOI: 10.1007/s00441-017-2604-1]

121 **Sabry D**, Mohamed A, Monir M, Ibrahim HA. The Effect of Mesenchymal Stem Cells Derived Microvesicles on the Treatment of Experimental CCL4 Induced Liver Fibrosis in Rats. *Int J Stem Cells* 2019; **12**: 400-409 [PMID: 31474025 DOI: 10.15283/ijsc18143]

122 **Rong X**, Liu J, Yao X, Jiang T, Wang Y, Xie F. Human bone marrow mesenchymal stem cells-derived exosomes alleviate liver fibrosis through the Wnt/β-catenin pathway. *Stem Cell Res Ther* 2019; **10**: 98 [PMID: 30885249 DOI: 10.1186/s13287-019-1204-2]

123 **Zhu Y**, Miao Z, Gong L, Chen W. Transplantation of mesenchymal stem cells expressing TIMP-1-shRNA improves hepatic fibrosis in CCl₄-treated rats. *Int J Clin Exp Pathol* 2015; **8**: 8912-8920 [PMID: 26464632]

124 **Wang X**, Wang H, Lu J, Feng Z, Liu Z, Song H, Wang H, Zhou Y, Xu J. Erythropoietin-Modified Mesenchymal Stem Cells Enhance Anti-fibrosis Efficacy in Mouse Liver Fibrosis Model. *Tissue Eng Regen Med* 2020; **17**: 683-693 [PMID: 32621283 DOI: 10.1007/s13770-020-00276-2]

125 **Meier RP**, Mahou R, Morel P, Meyer J, Montanari E, Muller YD, Christofilopoulos P, Wandrey C, Gonelle-Gispert C, Bühler LH. Microencapsulated human mesenchymal stem cells decrease liver fibrosis in mice. *J Hepatol* 2015; **62**: 634-641 [PMID: 25450712 DOI: 10.1016/j.jhep.2014.10.030]

126 **Du C**, Jiang M, Wei X, Qin J, Xu H, Wang Y, Zhang Y, Zhou D, Xue H, Zheng S, Zeng W. Transplantation of human matrix metalloproteinase-1 gene-modified bone marrow-derived mesenchymal stem cell attenuates CCL4-induced liver fibrosis in rats. *Int J Mol Med* 2018; **41**: 3175-3184 [PMID: 29512750 DOI: 10.3892/ijmm.2018.3516]

127 **Ma ZG**, Lv XD, Zhan LL, Chen L, Zou QY, Xiang JQ, Qin JL, Zhang WW, Zeng ZJ, Jin H, Jiang HX, Lv XP. Human urokinase-type plasminogen activator gene-modified bone marrow-derived mesenchymal stem cells attenuate liver fibrosis in rats by down-regulating the Wnt signaling pathway. *World J Gastroenterol* 2016; **22**: 2092-2103 [PMID: 26877613 DOI: 10.3748/wjg.v22.i6.2092]

128 **Fiore EJ**, Bayo JM, Garcia MG, Malvicini M, Lloyd R, Piccioni F, Rizzo M, Peixoto E, Sola MB, Atorrasagasti C, Alaniz L, Camilletti MA, Enguita M, Prieto J, Aquino JB, Mazzolini G. Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice. *Stem Cells Dev* 2015; **24**: 791-801 [PMID: 25315017 DOI: 10.1089/scd.2014.0174]

129 **Chang N**, Ge J, Xiu L, Zhao Z, Duan X, Tian L, Xie J, Yang L, Li L. HuR mediates motility of human bone marrow-derived mesenchymal stem cells triggered by sphingosine 1-phosphate in liver fibrosis. *J Mol Med (Berl)* 2017; **95**: 69-82 [PMID: 27543493 DOI: 10.1007/s00109-016-1460-x]

**Footnotes**

**Conflict-of-interest statement:** The authors declare that they have no conflicts of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Unsolicited manuscript

**Peer-review started:** August 21, 2020

**First decision:** October 18, 2020

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B, B, B, B

Grade C (Good): C

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** Caboclo JF, Chiba T, Chiu KW, Corrales FJ, Sipos F **S-Editor:** Huang P **L-Editor:** Filipodia **P-Editor:**

**Figure Legends**




**Figure 1** **Introduction of the main parts of the review.** First, bone marrow-derived mesenchymal stem cells (BM-MSCs) are introduced as a therapy for liver fibrosis, then the steps before transplantation (culture, strategies, and the choice of transplantation route) are discussed. After that, the efficiency of BM-MSCs for liver fibrosis *in vivo* are explained through studies that research the efficiency, studies that compare the therapy to other medication sources, and the strategies to enhance the therapeutic efficiency.



**Figure 2** **The transition from a healthy liver to liver fibrosis.** Different types of hepatotoxic agents produce mediators that induce inflammatory actions in hepatic cell types. Following chronic liver injury, symptoms associated with advanced hepatic fibrosis will appear. This can either lead to liver cirrhosis, liver failure, and portal hypertension or can be resolved under the conditions mentioned. HCV: Hepatitis C virus; LPS: Lipopolysaccharide.



**Figure 3** **Eminent sources of adult mesenchymal stem cells and the cells into which they can differentiate.** Eminent sources of adult mesenchymal stem cells are ordered through their therapeutic eminence index. Umbilical cord is the most eminent, followed by the placenta, adipose tissue, endometrium, dental pulp, and dermis. The least eminent sources are amniotic fluid, synovium, and breast milk. The cell types, such as neurons, enterocytes, osteocytes, and chondrocytes, into which the isolated mesenchymal stem cells can differentiate are variant.



**Figure 4** **Bone marrow extracted cells.** Bone marrow contains a variety of stem cell populations that can be extracted, either through specific growth factor media, such as that for multipotent adult progenitor cells (MAPCs) and mesenchymal stem cells (MSCs) or through flow cytometric cell sorting (FACS) technology, such as for the endothelial progenitor cells (EPCs), hematopoietic stem cells (HPSCs), and side population cells (SPs).




**Figure 5** **Potential contributions of bone marrow-derived mesenchymal stem cells to liver fibrosis.** Each of the presented elements represent a distinct mechanism that has a specific role that can contribute to alleviating liver fibrosis. BM-MSCs: Bone marrow-derived mesenchymal stem cells; HSCs: Hepatic stellate cells; KC: Kupffer cells.



**Figure 6** **Two main types of mesenchymal stem cell culture.** The two-dimensional (2D) culture using 2D dishes as a monolayer for fast expansion, and the three-dimensional (3D) culture with two main types of spheroid use: multiple cell-derived spheroid and single cell-derived sphere. MSCs: Mesenchymal stem cells.



**Figure 7** **Strategies to enhance bone marrow-derived mesenchymal stem cell therapeutic efficiency.** Genetic engineering and preconditioning used during the culture phase; tissue engineering used on a three-dimensional (3D) matrix and involving signaling molecules; cell-free therapy through the use of exomes and microvesicles. MSCs: Mesenchymal stem cells.



**Figure 8** **Bone marrow-derived mesenchymal stem celltransplantation routes for liver disease.** The routes are either direct (portal vein and hepatic artery) or indirect (peripheral vein, intrasplenic, intraperitoneal, bone marrow reconstitution, and extra-corporeal liver assist)*.* BM-MSCs:Bone marrow-derived mesenchymal stem cells.

**Table 1 Bone marrow-derived mesenchymal stem cell therapeutic efficiency compared to other treatments and other stem cell sources**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Year | Pathogenesis | Model | Route | BM-MSCs compared to | Effect on liver fibrosis | Efficiency comparison |
| [107] | 2020 | CCl4 | Rats | Penile vein | Standard therapy: resveratrol and silybum marianum | Decreased AST, ALT, MDA, ALP, TNF-α, and CYP450 and increased albumin, SOD, GSH, GST, and CAT | BM-MSCs were more efficient |
|  |  |  |  |  |  | Restored liver structure and function and markedly decreased the induced liver fibrosis |  |
| [108] | 2020 | CCl4 | Rats | Intravenous | Imatinib | High therapeutic potential of utilizing BM-MSCs and imatinib, either individually or combined | Combined treatment was the most efficient |
|  |  |  |  |  |  | Reduced serum levels of ALT, AST, and ALP concomitantly |  |
|  |  |  |  |  |  | Downregulated α-SMA, procollagen I, procollagen III, collagen IV, and laminin |  |
| [109] | 2018 | TAA | Rats | Right lobe of the liver | Simvastatin | Reduced TGF-β1, α-SMA, and collagen-1 expression | Combined treatment was more efficient |
|  |  |  |  |  |  | Inhibited TGF-β/Smad signaling |  |
|  |  |  |  |  |  | Sim-MSCs strongly inhibited the progression of TAA-induced hepatic fibrosis |  |
| [110] | 2016 | TAA | Rats | Intrahepatic | Decorin | DCN and BM-MSCs alleviated liver fibrosis through: (1) decreased proliferation of HSCs; (2) suppressed TGF-β/Smad signaling; and (3) antifibrotic effect | Combined treatment was more efficient |
| [111] | 2016 | CCl4 | Rats | Intravenous | Endothelial progenitor cells | Elevated albumin and reduced ALT concentrations | No statistically significant difference |
|  |  |  |  |  |  | UC-EPCs were more valuable in increasing gene expression of *HGF* and immunohistochemistry of α-SMA and Ki-67; BM-MSCs had significantly lower TGF-β compared to UC-EPCs |  |
| [112] | 2020 | CCl4 | Rats | Tail vein | Human UC CD34+ | Expressing liver-specific genes | BM-MSCs were less efficient |
|  |  |  |  |  |  | Decreased gene expression of profibrotic genes (*collagen Iα*, *TGFβ1*, *α-SMA*) and of albumin |  |
|  |  |  |  |  |  | Increased antifibrotic gene (*MMP-9*) expression and decreased proinflammatory gene (*TNF-α*) expression |  |
|  |  |  |  |  |  | Reduced ALT concentration |  |
| [113] | 2017 | CCl4 | Rats | Intravenous | WJ-MSCs | Decreased hepatic hydroxyproline content and the percentage of collagen proportionately | BM-MSCs were more efficient |
|  |  |  |  |  |  | Reduced α-SMA and myofibroblasts |  |
|  |  |  |  |  |  | Increased number of EpCAM+ hepatic progenitor cells along with Ki-67+ and human matrix metalloprotease-1+ (MMP-1+) cells |  |
| [114] | 2017 | CCI4 | Rats | Portal vein | AD-MSCs | Prevented activation and proliferation of HSCs, and promoted apoptosis of HSCs | Similar efficiency |
|  |  |  |  |  |  | Implantation of AD-MSCs exhibited slightly improved anti-inflammatory and antiliver fibrotic activities compared to BM-MSCs |  |
| [115] | 2018 | CCl4 | Rats | Intravenous and intrasplenic | Intravenous and intrasplenic route | Elevated serum albumin levels and reduced serum ALT levels | Intravenous route was more efficient |
|  |  |  |  |  |  | Decreased inflammation by reducing the gene expression of proinflammatory cytokines (*IL-1β*, *IL-6*, and *INF-γ*) |  |
|  |  |  |  |  |  | An antifibrotic effect *via* reduced profibrogenic factors (TGF-β1, α-SMA, CTGF) and increased antifibrogenic factors (CK18, HGF) |  |
|  |  |  |  |  |  | Increased VEGF protein levels |  |
| [116] | 2016 | CCl4 | Mice | Portal and tail vein | Tail and portal vein route | Reduced AST/ALT levels | There were no efficiency differences |
|  |  |  |  |  |  | Stimulated positive changes in serum bilirubin and albumin |  |
|  |  |  |  |  |  | Downregulated expression of integrins (600-7000-fold), TGF, and procollagen-α1 |  |

α-SMA: Alpha-smooth muscle actin; a-SMA: Anti-alpha-smooth muscle actin; AD-MSCs: Adipose-derived mesenchymal stem cells; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; AST: Aspartate aminotransferase; BM-MSCs: Bone marrow-mesenchymal stem cells; CAT: Catalase; CCl4: Carbon tetrachloride; CK18: Cytokeratin 18; CTGF: Connective tissue growth factor; CYP450: Cytochrome P450; DCN: Decorin; GSH: Glutathione reductase; GST: Glutathione S-transferase; HGF: Hepatocyte growth factor; HSCs: Hepatic stellate cells; IL-1β: Interleukin-1β; IL-6: Interleukin 6; MDA: Malondialdehyde; MMP: Matrix metalloproteinase; MSCs: Mesenchymal stem cells; Sim-MSCs: Simvastatin-mesenchymal stem cells; SOD: Superoxide dismutase; TAA: Thioacetamide; TGF-β: Transforming growth factor-beta; TNF-α: Tumor necrosis factor-alpha; UC CD34+: Umbilical cord blood CD34+; UC-EPCs: Umbilical cord-endothelial progenitor cells; WJ-MSCs: Wharton’s jelly-derived mesenchymal stem cells; VEGF: Vascular endothelial growth factor.

**Table 2 Strategies to enhance bone marrow-derived mesenchymal stem cell therapeutic efficiency**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Ref. | Year | Pathogenesis | Model | Route | Strategy | Strategy efficiency |
| [117] | 2020 | CCl4 | Mice | Tail vein | Preconditioning: autophagy regulation in BM-MSCs | Boosted antifibrotic potential primed by autophagy inhibition in BM-MSCs may be attributed to their suppressive effect on CD4+ and CD8+ lymphocytes infiltration and HSC proliferation, which were regulated by elevated PTGS2/PGE2 *via* a paracrine pathway |
|  |  |  |  |  |  | BM-MSC-based remedy in liver fibrosis and other inflammatory disorders |
| [118] | 2019 | CCL4 | Rats | Tail vein | Preconditioning: conditioned media | Increasing antioxidant enzyme activity |
|  |  |  |  |  |  | Increased gene expression levels attenuated by CCl4 up to basal levels |
|  |  |  |  |  |  | Normalized the organization apart from some dilated sinusoids and vacuolated cells |
|  |  |  |  |  |  | Improved morphological, immunohistochemical, and biochemical measures |
| [119] | 2016 | CCl4 | Rats | Tail vein | Preconditioning:  with melatonin | Enhanced homing ability of MSCs |
|  |  |  |  |  |  | Enhanced liver function |
|  |  |  |  |  |  | Enhanced the interaction of melatonin receptors and matrix enzymes |
|  |  |  |  |  |  | Expressed a high level of CD44 |
|  |  |  |  |  |  | Ability to differentiate into adipocytes and Schwann cells |
| [120] | 2017 | CCI4 | Rats | Tail vein | Preconditioning: with melatonin | High ability of homing into the injured liver (*P* ≤ 0.05 *vs* BM-MSCs) |
|  |  |  |  |  |  | Higher percentage of glycogen storage but a lower percentage of collagen and lipid accumulation (*P* ≤ 0.05 *vs* CCl4 + BM-MSCs) |
|  |  |  |  |  |  | Low expression of TGF-β1 and Bax and lower content of serum ALT but higher expressions of MMPs and Bcl2 |
|  |  |  |  |  |  | The effectiveness of MT preconditioning in cell therapy |
| [121] | 2019 | CCL4 | Rats | Tail vein | Cell-free therapy: MSC-derived macrovesicles BM- MSC-MVs | Increased serum albumin levels and *VEGF* quantitative gene expression (*P* < 0.05) |
|  |  |  |  |  |  | Decreased serum ALT enzyme levels, quantitative gene expression of *TGF-β*, collagen-1α, and *IL-1β* |
|  |  |  |  |  |  | Decreased the collagen deposition and improvement of the histopathological picture |
|  |  |  |  |  |  | Antifibrotic, anti-inflammatory, and proangiogenic effects |
| [122] | 2019 | CCl4 | Rats | Tail vein | Cell free therapy: hBM-MSCs-Ex | Inhibition of Wnt/β-catenin signaling (PPARγ, Wnt10b, Wnt3a, β-catenin) |
|  |  |  |  |  |  | Downregulation of downstream gene expression (cyclin D1, *WISP1*) |
| [123] | 2015 | CCl4 | Rats | Intravenous | Genetically modified BM-MSCs expressing TIMP-1-shRNA | Decreased TIMP-1 expression thereby regulating HSC survival |
|  |  |  |  |  |  | Decreased serum levels of ALT and AST, fibrotic areas, and collagens |
|  |  |  |  |  |  | Reduction of the fibrotic area |
|  |  |  |  |  |  | Restoration of the liver function |
| [124] | 2020 | CCl4 | Mice | Intraperitoneal injection | MSCs expressing EPO | Promoted cell viability and migration of BM-MSCs |
|  |  |  |  |  |  | Enhanced antiﬁbrotic efﬁcacy with higher cell viability and stronger migration ability |
|  |  |  |  |  |  | Alleviated liver ﬁbrosis |
| [125] | 2015 | BDL or CCl4 | Mice | Underneath the kidney capsule | Microencapsulated BM-MSCs | Activated HSCs |
|  |  |  |  |  |  | Released antiapoptotic (IL-6, IGFBP-2) and anti-inflammatory (IL-1Ra) cytokines |
|  |  |  |  |  |  | Decreased mRNA levels of collagen type I |
|  |  |  |  |  |  | Increased levels of MMPs |
| [126] | 2018 | CCl4 | Rats | Tail vein | Genetically modified BM-MSCs with human MMP-1 | Biochemical parameters and hepatic architecture improved |
|  |  |  |  |  |  | Decreased collagen content |
|  |  |  |  |  |  | Suppressed activation of HSCs |
|  |  |  |  |  |  | Improvement of both liver injury and fibrosis |
| [127] | 2016 | CCl4 | Rats | Tail vein | Human urokinase-type plasminogen activator gene-modified BM-MSCs | Decreased serum levels of ALT, AST, total bilirubin, hyaluronic acid, laminin, and procollagen type III |
|  |  |  |  |  | Genetically modified BM-MSCs with human urokinase-type plasminogen activator | Increased levels of serum albumin |
|  |  |  |  |  |  | Downregulated both protein and mRNA expression of β-catenin, Wnt4, and Wnt5a |
|  |  |  |  |  |  | Decreased the Wnt signaling pathway |
|  |  |  |  |  |  | Decreased mRNA and protein expression of molecules involved in Wnt signaling thus working as an antifibrotic |
| [128] | 2015 | TAA | Mice | Tail vein | Genetically modified BM-MSCs, MSCs engineered to produce IGF-I | Enhanced the effects of MSC transplantation |
|  |  |  |  |  |  | Decreased inflammatory responses |
|  |  |  |  |  |  | Decreased collagen deposition |
|  |  |  |  |  |  | Increased growth factor like-I, IGF-I, and HGF |
|  |  |  |  |  |  | Reduced fibrogenesis and the stimulation of hepatocellular proliferation |
| [129] | 2017 | CCl4, BDL | Mice | Intraperitoneal | BM-MSCs triggered by sphingosine 1-phosphate | Increased HuR expression and cytoplasmic localization |
|  |  |  |  |  |  | S1P-induced migration of HBM-MSCs *via* S1PR3 and HuR |
|  |  |  |  |  |  | HuR regulated *S1PR3* mRNA expression by binding with *S1PR3* mRNA 3’ UTR |
|  |  |  |  |  |  | S1P-induced HuR phosphorylation and cytoplasmic translocation *via* S1PR3 |
|  |  |  |  |  |  | HuR regulated S1PR3 expression by competing with miR-30e |

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BDL: Bile duct ligation; BM-MSCs: Bone marrow-mesenchymal stem cells; CCl4: Carbon tetrachloride; EPO: Erythropoietin; hBM-MSCs-Ex: Human BM-MSCs-exomes; HBM: Human bone marrow; HGF: Hepatocyte growth factor; HSCs: Hepatic stellate cells; IGF-I: Insulin growth factor like-I; IL: Interleukin; MMPs: Matrix metalloproteinases; MSCs: Mesenchymal stem cells; MT: Melatonin; MVs: Microvesicles; PGE2: Prostaglandin E2; PPARγ: Peroxisome proliferator-activated receptor-gamma; PTGS2: Prostaglandin-endoperoxide synthase-2; S1P: Sphingosine 1-phosphate; S1PR3: Sphingosine-1-phosphate receptor 3; TGF: Transforming growth factor; TIMP-1: Tissue inhibitor of metalloproteases 1; UTR: Untranslated region; VEGF: Vascular endothelial growth factor; WISP1: Wnt-1-induced secreted protein 1.